Related Experiment Videos
Early ribavarin treatment of bronchiolitis: effect on long-term respiratory morbidity
Dean Edell1, Vikram Khoshoo, Gerald Ross
1West Jefferson Medical Center, New Orleans, LA, USA.
Insights
Early ribavirin treatment for respiratory syncytial virus (RSV) bronchiolitis in infants significantly reduced long-term respiratory issues. This approach lowered reactive airway disease and hospitalizations, improving infant respiratory health outcomes.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pulmonology
Background:
- Mortality from respiratory syncytial virus (RSV) bronchiolitis has decreased.
- Long-term respiratory morbidity after RSV bronchiolitis is a growing concern.
- Focus shifts to managing post-RSV respiratory complications.
Purpose of the Study:
- To evaluate the efficacy of early ribavirin treatment in reducing long-term respiratory morbidity in infants with severe RSV bronchiolitis.
- To assess the impact of ribavirin on reactive airway disease and hospitalizations.
Main Methods:
- Prospective randomized study of 49 previously healthy infants with severe RSV bronchiolitis.
- Infants received either conservative treatment or additional ribavirin within 5 days of illness onset.
- One-year follow-up to monitor respiratory outcomes and hospitalizations.
Main Results:
- Ribavirin group showed significantly fewer episodes of reactive airway disease (2.7 vs 6.4 episodes/patient/year).
- Reduced severity of reactive airway disease in the ribavirin group (0.08 vs 1.09 moderate-to-severe episodes/patient/year).
- Significantly fewer respiratory illness-related hospitalizations in the ribavirin group (25 vs 90 days/100 patients/year).
Conclusions:
- Early ribavirin treatment for RSV bronchiolitis in infants reduces the incidence and severity of reactive airway disease.
- Ribavirin therapy also decreases respiratory illness-related hospitalizations.
- This suggests a beneficial role for early ribavirin in managing RSV bronchiolitis and its long-term respiratory sequelae.
Background:
The mortality rate from respiratory syncytial virus (RSV) bronchiolitis has significantly reduced over the last decade. A major concern now is the long-term respiratory morbidity following RSV bronchiolitis.
Methods:
In this prospective study, we randomly assigned 49 previously healthy infants with severe RSV bronchiolitis, early in the course of illness (< 5 days duration), to receive either conservative treatment (n = 21) or additional ribavirin treatment (n = 24). Both groups were closely matched for age and clinical characteristics.
Results:
During a prospective, closely monitored, 1-year follow-up period, the group treated with ribavirin had significantly fewer episodes (2.7 +/- 2.3 episodes vs 6.4 +/- 4.2 episodes per patient per year) and reduced severity of reactive airway disease (0.08 episodes vs 1.09 episodes of moderate-to-severe illness per patient per year) and respiratory illness-related hospitalization (25 hospital days vs 90 hospital days per 100 patients per year).
Conclusions:
Early ribavirin treatment of RSV bronchiolitis in previously healthy infants resulted in reduction of incidence and severity of reactive airway disease as well as respiratory illness-related hospitalization.